Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Trend Micro: Rekordumsatz im Q2 2026, aber Gewinneinbruch und gesenkte Prognose belasten die Aktie (Investing.com DE) +++ TREND MICRO Aktie +3,25%

CARDIOL Aktie

 >CARDIOL Aktienkurs 
1.23 EUR    -6.5%    (TradegateBSX)
Ask: 1.26 EUR / 800 Stück
Bid: 1.244 EUR / 2000 Stück
Tagesumsatz: 1200 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
CARDIOL Aktie über LYNX handeln
>CARDIOL Performance
1 Woche: +13,0%
1 Monat: +43,0%
3 Monate: +13,4%
6 Monate: +45,7%
1 Jahr: +36,7%
laufendes Jahr: +54,4%
>CARDIOL Aktie
Name:  CARDIOL THERAPEUTICS CL.A
Land:  Kanada
Sektor:  Gesundheit
ISIN/ Wkn:  CA14161Y2006 / A2PA9E
Symbol/ Ticker:  CT9 (Frankfurt) / CRDL (NASDAQ)
Kürzel:  FRA:CT9, ETR:CT9, CT9:GR, NASDAQ:CRDL
Index:  -
Webseite:  https://www.cardiolrx.com..
Profil:  Cardiol Therapeutics Inc. is a clinical-stage biotechnology company that focuses on developing innovative therapies for heart diseases. The company's primary objective is to research and produce anti-inflammatory and anti-fibrotic treatments aimed at..
>Volltext..
Marktkapitalisierung:  148.13 Mio. EUR
Unternehmenswert:  131.01 Mio. EUR
Umsatz:  -
EBITDA:  -22.08 Mio. EUR
Nettogewinn:  -22.62 Mio. EUR
Gewinn je Aktie:  -0.24 EUR
Schulden:  0.07 Mio. EUR
Liquide Mittel:  17.22 Mio. EUR
Operativer Cashflow:  -15.07 Mio. EUR
Bargeldquote:  3.88
Umsatzwachstum:  -
Gewinnwachstum:  1.59%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  CARDIOL
Letzte Datenerhebung:  13.08.26
>CARDIOL Kennzahlen
Aktien/ Unternehmen:
Aktien: 115.89 Mio. St.
Frei handelbar: 97.04%
Leerverk. Aktien: 1.94%
Rückkaufquote: -12.27%
Mitarbeiter: 23
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 410.7%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 8.71
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -127.85%
Eigenkaprendite: -173.96%
>CARDIOL Peer Group
Gesundheit, Cannabis- Produkte, Herz-Kreislauf- Behandlung/ Kardiologie
 
11.08.26 - 16:01
 Cardiol Therapeutics bei Canaccord Genuity: Phase-III-Katalysator rückt näher (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
05.08.26 - 13:30
 Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity′s 46th Annual Growth Conference (PR Newswire)
 
TORONTO, Aug. 5, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a......
14.07.26 - 13:30
 Cardiol Therapeutics′ Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association (PR Newswire)
 
• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion. TORONTO, July 14, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences......
09.07.26 - 13:31
 Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit (PR Newswire)
 
TORONTO, July 9, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a......
25.06.26 - 13:30
 Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders (PR Newswire)
 
TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces the results from its Annual General Meeting of......
23.06.26 - 13:30
 Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT (PR Newswire)
 
TORONTO, June 23, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces that the Company's virtual Annual General......
14.05.26 - 13:30
 Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ (PR Newswire)
 
TORONTO, May 14, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a......
07.05.26 - 13:31
 Cardiol Therapeutics′ Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association (PR Newswire)
 
Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, which recently surpassed 75% enrollment. TORONTO, ON, May 7, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ:......
28.04.26 - 13:30
 Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program (PR Newswire)
 
Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia University–NewYork-Presbyterian, NYU Langone Health, Lenox Hill Hospital/Northwell Health, and Houston Methodist Hospital. Growing......
14.04.26 - 13:42
 Cardiol Therapeutics Inc.: Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the......
01.04.26 - 13:42
 Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Year-End 2025 Update on Operations (Newsfile)
 
Initiated pivotal Phase III MAVERIC trial of CardiolRx in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026.Reported positive Phase II ARCHER da......
25.02.26 - 13:49
 Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing ......
23.01.26 - 15:30
 Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing t......
16.01.26 - 15:27
 XFRA: CT9: Wiederaufnahme/Resumption (XETRA)
 
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN CARDIOL THERAPEUTICS CL.A CT9 CA14161Y2006 AB/FROM ONWARDS 16.01.2026 15:13 CET...
16.01.26 - 15:03
 XFRA: CT9: Aussetzung/Suspension (XETRA)
 
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL CARDIOL THERAPEUTICS CL.A CT9 CA14161Y2006 BAW/UFN...
16.01.26 - 15:03
 Cardiol Therapeutics announces $13.5M bought-deal private placement (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
16.01.26 - 14:54
 Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing t......
16.01.26 - 14:54
 Cardiol Therapeutics Inc.: Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million (Newsfile)
 
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing t......
16.01.26 - 14:48
 XFRA: INSTRUMENT_SUSPENSION - CA14161Y2006 (XETRA)
 
Instrument ID [6186088] (CT9 - CA14161Y2006) suspended...
13.01.26 - 13:42
 Cardiol Therapeutics Inc.: Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis (Newsfile)
 
Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients.Activation of additional top-tier clinical sites in Europe ......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Die Absicht eines Christen, der ein Streitgespräch über die Glaubenswahrheiten führt, muß nicht darauf zielen, den Glauben zu beweisen, sondern den Glauben zu verteidigen. - Hl. Thomas von Aquin
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!